HKEY-AI-NAM-Bridge\u2122 1.0<\/b> connects AI predictions, new approach methodologies and in vivo evidence for more targeted preclinical study design<\/p>\n
BOSTON and SUZHOU, China<\/span>, July 13, 2026<\/span> \/PRNewswire\/ — HKeyBio has established HKEY-AI-NAM-Bridge\u2122 1.0<\/b>, its AI and New Approach Methodologies (NAMs) In Vivo Evidence Bridging Package. The service helps autoimmune and allergy drug-development teams identify evidence gaps and design more targeted in vivo validation paths from AI predictions, in vitro assays, organ-on-chip, cell-based, omics and preliminary PK data.<\/p>\n HKEY-AI-NAM-Bridge\u2122 1.0 at a Glance<\/b><\/p>\n What it is:<\/b> HKEY-AI-NAM-Bridge\u2122 1.0 is HKeyBio’s preclinical evidence-bridging service for AI, NAMs and in vivo validation.<\/p>\n Problem addressed:<\/b> It helps identify evidence gaps between AI predictions, in vitro systems, omics or organ-on-chip data and disease-relevant in vivo evidence.<\/p>\n Use cases:<\/b> The service is designed for programs with existing AI prediction, in vitro, cell model, organ-on-chip, omics or preliminary PK data.<\/p>\n HKeyBio capability link:<\/b> The service draws on HKeyBio’s in vivo efficacy evaluation, NHP models, pathology, immune phenotyping, biomarkers and translational interpretation.<\/p>\n AI and NAMs help design smarter in vivo studies<\/b><\/p>\n HKEY-AI-NAM-Bridge\u2122 1.0 is based on a practical principle: AI and NAMs do not simply replace animal studies; they can help design more targeted and more interpretable in vivo studies.<\/p>\n The package focuses on evidence gaps, minimal study design and bridging endpoints<\/b><\/p>\n 1. Evidence gap analysis<\/b><\/p>\n Identifies gaps such as in vitro activity without disease-model efficacy, binding without downstream function, AI prediction without target engagement, or mouse data without cross-species interpretation.<\/p>\n 2. Minimal in vivo validation questions<\/b><\/p>\n Prioritizes the few critical questions that an in vivo study should answer first.<\/p>\n 3. Bridging endpoint design<\/b><\/p>\n Connects pharmacodynamic endpoints, mechanism endpoints, translational biomarkers, PK exposure, PK\/PD correlation and basic safety observations.<\/p>\n HKeyBio integrates disease models, NHP research and translational reporting<\/b><\/p>\n Deliverables may include existing evidence summary, evidence gap assessment, in vivo validation rationale, minimal animal study design, biomarker and PK\/PD bridging plan, NHP necessity assessment, IND-enabling relevance, risk and limitation statement and next-step recommendation.<\/p>\n “A more responsible approach is to use AI, in vitro and NAM data to ask better questions, and then validate the critical evidence in disease-relevant in vivo models,” said the Head of Translational Medicine at HKeyBio.<\/p>\n About HKeyBio<\/b><\/p>\n HKeyBio is a preclinical CRO specializing in autoimmune and allergic diseases, supported by animal models, NHP models, pathology, immunology assays, PK\/PD, biomarkers and English-language translational reporting.<\/p>\n For more information, please contact: <\/p>\n HKEY-AI-NAM-Bridge\u2122 1.0<\/b> connects AI predictions, new approach methodologies and in vivo evidence for more targeted preclinical study design<\/p>\n BOSTON and SUZHOU, China<\/span>, July 13, 2026<\/span> \/PRNewswire\/ — HKeyBio has established HKEY-AI-NAM-Bridge\u2122 1.0<\/b>, its AI and New Approach Methodologies (NAMs) In Vivo Evidence Bridging Package. The service helps autoimmune and allergy drug-development teams identify evidence gaps and design more targeted in vivo validation paths from AI predictions, in vitro assays, organ-on-chip, cell-based, omics and preliminary PK data.<\/p>\n HKEY-AI-NAM-Bridge\u2122 1.0 at a Glance<\/b><\/p>\n What it is:<\/b> HKEY-AI-NAM-Bridge\u2122 1.0 is HKeyBio’s preclinical evidence-bridging service for AI, NAMs and in vivo validation.<\/p>\n Problem addressed:<\/b> It helps identify evidence gaps between AI predictions, in vitro systems, omics or organ-on-chip data and disease-relevant in vivo evidence.<\/p>\n Use cases:<\/b> The service is designed for programs with existing AI prediction, in vitro, cell model, organ-on-chip, omics or preliminary PK data.<\/p>\n HKeyBio capability link:<\/b> The service draws on HKeyBio’s in vivo efficacy evaluation, NHP models, pathology, immune phenotyping, biomarkers and translational interpretation.<\/p>\n AI and NAMs help design smarter in vivo studies<\/b><\/p>\n HKEY-AI-NAM-Bridge\u2122 1.0 is based on a practical principle: AI and NAMs do not simply replace animal studies; they can help design more targeted and more interpretable in vivo studies.<\/p>\n The package focuses on evidence gaps, minimal study design and bridging endpoints<\/b><\/p>\n 1. Evidence gap analysis<\/b><\/p>\n Identifies gaps such as in vitro activity without disease-model efficacy, binding without downstream function, AI prediction without target engagement, or mouse data without cross-species interpretation.<\/p>\n 2. Minimal in vivo validation questions<\/b><\/p>\n Prioritizes the few critical questions that an in vivo study should answer first.<\/p>\n 3. Bridging endpoint design<\/b><\/p>\n Connects pharmacodynamic endpoints, mechanism endpoints, translational biomarkers, PK exposure, PK\/PD correlation and basic safety observations.<\/p>\n HKeyBio integrates disease models, NHP research and translational reporting<\/b><\/p>\n Deliverables may include existing evidence summary, evidence gap assessment, in vivo validation rationale, minimal animal study design, biomarker and PK\/PD bridging plan, NHP necessity assessment, IND-enabling relevance, risk and limitation statement and next-step recommendation.<\/p>\n “A more responsible approach is to use AI, in vitro and NAM data to ask better questions, and then validate the critical evidence in disease-relevant in vivo models,” said the Head of Translational Medicine at HKeyBio.<\/p>\n About HKeyBio<\/b><\/p>\n HKeyBio is a preclinical CRO specializing in autoimmune and allergic diseases, supported by animal models, NHP models, pathology, immunology assays, PK\/PD, biomarkers and English-language translational reporting.<\/p>\n For more information, please contact: <\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-64579","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/64579","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=64579"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/64579\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=64579"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=64579"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=64579"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
<\/b>Website: www.hkeybio.com<\/a>
Email: tech@hkeybio.com<\/a>\u00a0<\/p>","protected":false},"excerpt":{"rendered":"
<\/b>Website: www.hkeybio.com<\/a>
Email: tech@hkeybio.com<\/a>\u00a0<\/p>\n